Drug Profile
Research programme: peptide therapeutics - Susavion Biosciences
Alternative Names: sv 6B; sv 6D; svC 2; svH 1C; svH 1D; svL 4Latest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Susavion Biosciences
- Developer California Department of Health Services; Susavion Biosciences; University of Patras
- Class Antineoplastics; Antivirals; Peptides
- Mechanism of Action Lectin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Viral infections
Most Recent Events
- 23 Aug 2023 Preclinical development is ongoing in USA (Susavion Biosciences pipeline, August 2023)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Jul 2019 No recent reports of development identified for preclinical development in Viral-infections in USA